1 Table of Contents 1 Table of Contents 5 1.1 List of Tables 8 1.2 List of Figures 8 2 Introduction 10 2.1 Disease Introduction 10 2.2 Epidemiology 10 2.3 Disease Classification 11 2.4 Symptoms 13 2.5 Etiology and Pathophysiology 14 2.5.1 Etiology 14 2.5.2 Pathophysiology 15 2.6 Diagnosis 17 2.6.1 Biomarkers 19 2.7 Prognosis 20 2.8 Treatment Guidelines and Options 21 2.8.1 Treatment Options 21 3 Marketed Products 28 3.1 Overview 28 3.1.1 Aptiom/Zebinix (Eslicarbazepine acetate) - BIAL-Portela 29 3.1.2 Banzel/Inovelon (Rufinamide) - Novartis 30 3.1.3 Briviact (Brivaracetam) - UCB 31 3.1.4 Fycompa (perampanel) - Eisai 32 3.1.5 Keppra (levetiracetam) - UCB 34 3.1.6 Lyrica (pregabalin) - Pfizer 36 3.1.7 Vimpat (lacosamide) - UCB 37 3.1.8 Lamictal (lamotrigine) - GSK 39 3.1.9 Epidiolex (Cannabidiol) - GW Pharmaceuticals 40 3.1.10 Older Generation AEDs 41 3.2 Comparative Efficacy and Safety of Marketed Product 42 4 Pipeline Analysis 44 4.1 Overview 44 4.2 Pipeline Distribution by Stage of Development, Molecule Type, Route of Administration and Program Type 44 4.3 Pipeline Distribution by Molecular Target 45 4.4 Promising Pipeline Candidates 48 4.4.1 Fintepla (low-dose fenfluramine Hydrochloride/ZX-008) - Zogenix 48 4.4.2 Cenobamate (YKP3089) - SK Biopharmaceuticals 50 4.5 Comparative Efficacy and Safety of Pipeline Products 52 4.6 Product Competitiveness Framework 53 5 Clinical Trial Analysis 54 5.1 Failure Rate 54 5.1.1 Overall Failure Rate 54 5.1.2 Failure Rate by Phase and Molecule Type 55 5.1.3 Failure Rate by Phase and Molecular Target 55 5.2 Clinical Trial Size 56 5.2.1 Patient Enrollment per Product by Molecule Type and Stage of Development 56 5.2.2 Patient Enrollment per Product by Molecular Target and Stage of Development 57 5.2.3 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development 58 5.2.4 Patient Enrollment per Trial by Molecular Target and Stage of Development 59 5.3 Clinical Trial Duration 60 5.3.1 Clinical Trial Duration by Molecule Type 60 5.3.2 Clinical Trial Duration by Molecular Target 61 5.4 Competitive Clinical Trials Metrics Analysis 62 6 Multi-scenario Forecast 64 6.1 Geographical Markets 64 6.2 Asia-Pacific Market 65 6.3 India 66 6.3.1 Treatment Usage Patterns 66 6.3.2 Annual Cost of Therapy 68 6.3.3 Market Size 69 6.4 China 70 6.4.1 Treatment Usage Patterns 70 6.4.2 Annual Cost of Therapy 71 6.4.3 Market Size 72 6.5 Australia 73 6.5.1 Treatment Usage Patterns 73 6.5.2 Annual Cost of Therapy 74 6.5.3 Market Size 75 6.6 South Korea 76 6.6.1 Treatment Usage Patterns 76 6.6.2 Annual Cost of Therapy 77 6.6.3 Market Size 78 6.7 Japan 79 6.7.1 Treatment Usage Patterns 79 6.7.2 Annual Cost of Therapy 80 6.7.3 Market Size 82 7 Drivers and Barriers 83 7.1 Drivers 83 7.1.1 Improved Economy and Affordability Boost the Market 83 7.1.2 Promising Pipeline Products that Target Unmet Needs for Epilepsy 83 7.1.3 Government-Sponsored Increased Awareness and Access to Healthcare will Improve Epilepsy Treatment 83 7.2 Barriers 84 7.2.1 Social Stigma and Lack Awareness to Hamper Low Diagnosis and Treatment Rates 84 7.2.2 Impending Patent Cliffs and Generic Erosion 84 7.2.3 Lack of Strong Patent Protection or Intellectual Property Rights. 84 8 Deals and Strategic Consolidations 85 8.1 Licensing Deals 85 8.1.1 Deals by Region and Value 85 8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 86 8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 87 8.2 Key Licensing Deals 90 8.3 Co-development Deals 91 8.3.1 Deals by Region and Value 91 8.3.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 92 8.3.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 93 8.4 Key Co-development Deals 96 9 Appendix 98 9.1 All Pipeline Drugs by Stage of Development 98 9.1.1 Discovery 98 9.1.2 Preclinical 99 9.1.3 IND/CTA-filed 103 9.1.4 Phase I 103 9.1.5 Phase II 104 9.1.6 Phase III 105 9.1.7 Pre-registration 106 9.2 Summary of Multi-scenario Market Forecasts to 2024 107 9.2.1 Asia-Pacific 107 9.2.2 India 107 9.2.3 China 107 9.2.4 Australia 108 9.2.5 South Korea 108 9.2.6 Japan 109 9.3 Bibliography 109 9.4 Abbreviations 114 9.5 Research Methodology 116 9.5.1 Secondary Research 117 9.5.2 Marketed Product Profiles 117 9.5.3 Late-Stage Pipeline Candidates 117 9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 117 9.5.5 Product Competitiveness Framework 118 9.5.6 Pipeline Analysis 118 9.5.7 Forecasting Model 119 9.5.8 Deals Data Analysis 119 9.6 Contact Us 120 9.7 Disclaimer 120

1.1 List of Tables Table 1: Epilepsy Therapeutics, Global, Types of Seizures, 2017 12 Table 2: Causes of Epilepsy According to Age 14 Table 3: Examples of Biomarkers Needed in Different Epilepsy Indications 20 Table 4: AED Options by Seizure Type 22 Table 5: Epilepsy Therapeutics Market, Global, Licensing Deals Valued Above $10m, 2007-2018 91 Table 6: Epilepsy Therapeutics Market, Global, Co-development Deals, 2007-2018 97 Table 7: Epilepsy Therapeutics Market, Global, All Pipeline Products, Discovery, 2018 98 Table 8: Epilepsy Therapeutics Market, Global, All Pipeline Products, Preclinical, 2018 99 Table 9: Epilepsy Therapeutics Market, Global, All Pipeline Products, IND/CTA-filed, 2018 103 Table 10: Epilepsy Therapeutics Market, Global, All Pipeline Products, Phase I, 2018 103 Table 11: Epilepsy Therapeutics Market, Global, All Pipeline Products, Phase II, 2018 104 Table 12: Epilepsy Therapeutics Market, Global, All Pipeline Products, Phase III, 2018 105 Table 13: Epilepsy Therapeutics Market, Global, All Pipeline Products, Pre-registration, 2018 106 Table 14: Epilepsy Therapeutics Market, Asia-Pacific, Market Forecast, 2017-2024 107 Table 15: Epilepsy Therapeutics Market, India, Market Forecast, 2017-2024 107 Table 16: Epilepsy Therapeutics Market, China, Market Forecast, 2017-2024 107 Table 17: Epilepsy Therapeutics Market, Australia, Market Forecast, 2017-2024 108 Table 18: Epilepsy Therapeutics Market, South Korea, Market Forecast, 2017-2024 108 Table 19: Epilepsy Therapeutics Market, Japan, Market Forecast, 2017-2024 1091.2 List of Figures Figure 1: Epilepsy Therapeutics Market, Patient Distribution in APAC 10 Figure 2: Summary of the Pathophysiology of Seizures by Net Increased Neuronal Excitation 16 Figure 3: Algorithm for investigation of patient presenting with seizure 18 Figure 4: Algorithm for Choice of AED for New-Onset Epilepsy Patients 26 Figure 5: Treatment Algorithm for Status Epilepticus in Australia 27 Figure 6: Epilepsy Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products 43 Figure 7: Pipeline for Epilepsy Therapeutics, Global, 2018 45 Figure 8: Pipeline for Epilepsy Therapeutics by Molecular Target, Global, 2018 47 Figure 9: Epilepsy Therapeutics Market, APAC, ZX008 Forecast ($m), 2020-2024 50 Figure 10: Epilepsy Therapeutics Market, APAC, Cenobamate Forecast ($m), 2020-2024 51 Figure 11: Epilepsy Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products 52 Figure 12: Epilepsy Therapeutics Market, Competitor Matrix for Epilepsy Marketed and Pipeline Products 53 Figure 13: Epilepsy Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2007-2017 55 Figure 14: Epilepsy Therapeutics, Global, Clinical Trial Failure Rates by Molecular Target (%), 2007-2017 56 Figure 15: Epilepsy Therapeutics, Global, Clinical Trial Size per Product by Molecule Type (participants), 2007-2017 57 Figure 16: Epilepsy Therapeutics, Global, Clinical Trial Size per Product by Molecular Target (participants), 2007-2017 58 Figure 17: Epilepsy Therapeutics, Global, Clinical Trial Size per Trial by Molecule Type (participants), 2007-2017 59 Figure 18: Epilepsy Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target (participants), 2007-2017 60 Figure 19: Epilepsy Therapeutics, Global, Clinical Trial Duration by Molecule Type (months), 2007-2017 61 Figure 20: Epilepsy Therapeutics, Global, Clinical Trial Duration by Molecular Target (months), 2007-2017 62 Figure 21: Epilepsy Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type 62 Figure 22: Epilepsy Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target 63 Figure 23: Epilepsy Therapeutics Market, Asia-Pacific, Treatment Patterns (million), 2017-2024 65 Figure 24: Epilepsy Therapeutics Market, APAC, Market Size ($m), 2017-2024 66 Figure 25: Epilepsy Therapeutics Market, India, Treatment Patterns (million), 2017-2024 67 Figure 26: Epilepsy Therapeutics Market, India, Annual Cost of Therapy ($), 2017-2024 69 Figure 27: Epilepsy Therapeutics Market, India, Market Size ($m), 2017-2024 70 Figure 28: Epilepsy Therapeutics Market, China, Treatment Patterns (million), 2017-2024 71 Figure 29: Epilepsy Therapeutics Market, China, Annual Cost of Therapy ($), 2017-2024 72 Figure 30: Epilepsy Therapeutics Market, China, Market Size ($m), 2017-2024 73 Figure 31: Epilepsy Therapeutics Market, Australia, Treatment Patterns (‘000), 2017-2024 74 Figure 32: Epilepsy Therapeutics Market, Australia, Annual Cost of Therapy ($), 2017-2024 75 Figure 33: Epilepsy Therapeutics Market, Australia, Market Size ($m), 2017-2024 76 Figure 34: Epilepsy Therapeutics Market, South Korea, Treatment Patterns (‘000), 2017-2024 77 Figure 35: Epilepsy Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2017-2024 78 Figure 36: Epilepsy Therapeutics Market, South Korea, Market Size ($m), 2017-2024 79 Figure 37: Epilepsy Therapeutics Market, Japan, Treatment Patterns (000), 2017-2024 80 Figure 38: Epilepsy Therapeutics Market, Japan, Annual Cost of Therapy ($), 2017-2024 81 Figure 39: Epilepsy Therapeutics Market, Japan, Market Size ($m), 2017-2024 82 Figure 40: Epilepsy Therapeutics Market, Global, Licensing Deals By Region And Value, 2007-2018 86 Figure 41: Epilepsy Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2007-2018 87 Figure 42: Epilepsy Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2007-2018 88 Figure 43: Epilepsy Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2007-2018 89 Figure 44: Epilepsy Therapeutics Market, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2007-2018 90 Figure 45: Epilepsy Therapeutics Market, Global, Co-development Deals by Region and Deal Value, 2007-2018 92 Figure 46: Epilepsy Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2008-2018 93 Figure 47: Epilepsy Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2007-2018 94 Figure 48: Epilepsy Therapeutics Market, Global, Co-development Deals by Molecule Type and Stage of Development, 2007-2018 95 Figure 49: Epilepsy Therapeutics Market, Global, Co-development Deals by Molecular Target, 2007-2018 95